Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 30, 2014
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical...
-
Aug 30, 2014Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical...
-
Jul 11, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...
-
Jun 26, 2014
Boston Scientific welcomes the National Institute for Health and Care Excellence (NICE) guidance on the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy...
-
Jun 26, 2014
Boston Scientific welcomes the National Institute for Health and Care Excellence (NICE) guidance on the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy...
-
Jun 26, 2014
Boston Scientific begrüßt die neuen Leitlinien des „National Institute for Health and Care Excellence“ (NICE) zum Einsatz von implantierbaren Kardioverter-Defibrillatoren (ICD) und Geräten...
-
Jun 14, 2014
Un video, resumen el congreso EuroPCR, que incluye los últimos resultados de los estudios clínicos EVOLVE y REPRISE II presentados por Dr. Kieth Oldroyd y Dr Daniel Blackman. Exención de...
-
Jun 14, 2014
Un breve video che racconta il congresso EuroPCR 2014, compresi gli ultimi dati clinici dagli studi EVOLVE e REPRISE II, presentati dal Dr. Keith G. Oldroyd e dal Dr. Daniel Blackman. ATTENZIONE:...
-
Jun 14, 2014
Un breve video che racconta il congresso EuroPCR 2014, compresi gli ultimi dati clinici dagli studi EVOLVE e REPRISE II, presentati dal Dr. Keith G. Oldroyd e dal Dr. Daniel Blackman.